Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 15, 2011

Ono Pays Kai $13M for Japanese Rights to Phase II Secondary Hyperparthyrodism Drug

  • Ono Pharmaceutical is paying Kai Pharmaceuticals $13 million up front for Japanese development and commercialization rights to the latter’s lead candidate KAI-4169. It is in Phase II development as an intravenously administered treatment for secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease-mineral and bone disorder (CKD-MBD).

    The deal gives Ono Japanese rights to all indications for injectable formulations of KAI-4169. Kai will receive additional development, regulatory, and commercial milestones plus royalties on Ono’s sales of resulting products.

    KAI-4169 is a peptide agonist of the human cell surface calcium-sensing receptor (CaSR). Positive data from a Phase I single ascending-dose study in healthy volunteers and end-stage renal disease patients with CKD-MBD following hemodialysis were reported in March. The results showed that KAI-4169 was safe and well tolerated and resulted in significant and sustained dose-dependent reductions in serum PTH levels.

    KAI-4169 is also in preclinical development as a transdermal patch product for daily administration in the treatment of stage 3 and 4 CKD-MBD predialysis patients, ESRD (stage 5 kidney disease) patients receiving peritoneal dialysis, renal transplant patients with CKD-MBD, and primary hyperparathyroid patients who are ineligible to undergo parathyroidectomy. 

Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »